Bertea M et al. |
Deoxysphingoid bases as plasma markers in diabetes mellitus. |
2010 |
Lipids Health Dis |
pmid:20712864
|
Baird RD et al. |
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. |
2009 |
Mol. Cancer Ther. |
pmid:19509256
|
Sánchez AM et al. |
Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation. |
2008 |
Eur. J. Pharmacol. |
pmid:18343365
|
Pruett ST et al. |
Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols. |
2008 |
J. Lipid Res. |
pmid:18499644
|
Salcedo M et al. |
The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway. |
2007 |
Apoptosis |
pmid:17191124
|
Den Brok MW et al. |
Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices. |
2006 |
Pharmazie |
pmid:16454201
|
Faircloth G and Cuevas C |
Kahalalide F and ES285: potent anticancer agents from marine molluscs. |
2006 |
Prog. Mol. Subcell. Biol. |
pmid:17153351
|
Den Brok MW et al. |
Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl. |
2005 Jul-Aug |
PDA J Pharm Sci Technol |
pmid:16218203
|
Stokvis E et al. |
A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285. |
2004 |
Biomed. Chromatogr. |
pmid:15273982
|
Yun JM et al. |
Efficient synthesis of enantiomerically pure 2-acylaziridines: Facile syntheses of N-Boc-safingol, N-Boc-D-erythro-sphinganine, and N-Boc-spisulosine from a common intermediate. |
2003 |
J. Org. Chem. |
pmid:14510541
|